Market Capitalization (Millions $) |
4 |
Shares
Outstanding (Millions) |
1 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
40 |
Cash Flow (TTM) (Millions $) |
-1 |
Capital Exp. (TTM) (Millions $) |
2 |
Polypid Ltd
Polypid Ltd is a biopharmaceutical company that specializes in developing and commercializing novel drugs for the prevention and treatment of infectious diseases. The company's focus is on creating innovative, long-acting antibiotic therapies that help overcome antimicrobial resistance and improve patient outcomes. Polypid's proprietary technology platform, known as PolyPid Controlled Release System, allows for the controlled release of drugs at specific target sites, ensuring a prolonged and effective therapy. Their product pipeline includes potential treatments for a range of bacterial infections, including surgical site infections and chronic osteomyelitis. Polypid is dedicated to addressing the global healthcare challenge of drug-resistant infections and improving the quality of life for patients.
Company Address: 18 Hasivim Street Petach Tikva 495376 NJ
Company Phone Number: 858-5995 Stock Exchange / Ticker: NASDAQ PYPD
PYPD is expected to report next financial results on March 30, 2024. |
|
|